secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001437749-24-022952
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences settles shareholder derivative suit; CEO bonus now tied to FDA approval of simufilam
--------------------------------------------------------------------------------

- Settlement modifies CEO Remi Barbier's $74.9M bonus: payment requires FDA approval of simufilam or recalculation upon sale.
- Corporate governance reforms: new Compensation Disclosure Committee, retention of compensation consultant by board.
- Court approval hearing set for Sept 9, 2024; settlement includes dismissal of derivative claims with prejudice.
- Cassava also achieved removal of non-employee directors from bonus plan and appointment of three independent directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924022952/0001437749-24-022952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924022952/sava20240716_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer